1. No later than 2 January 2032, the Commission shall assess and adopt a report on the appropriateness and cost-benefit ratio of including in the common data platform the following chemicals data relating to medicinal products pursuant to Article 3(3):
|
(a)
|
new categories of data types;
|
|
(b)
|
chemicals data on substances other than active substances;
|
|
(c)
|
chemicals data on active substances that do not meet the criteria referred to in Article 3(3), point (b);
|
|
(d)
|
chemicals data collected and submitted under Union legal acts listed in Annex I, Part 2, and held by competent authorities of the Member States and not by the Agencies.
|